259219-18-6

Basic information

• Product Name: 3-nitro-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester
• Synonyms: 3-nitro-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester
• CAS NO: 259219-18-6
• Molecular Weight: 382.459
• Mol File: 259219-18-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-nitro-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester(259219-18-6)
• EPA Substance Registry System: 3-nitro-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester(259219-18-6)

Safety Data

• Hazardous Substances Data: 259219-18-6(Hazardous Substances Data)

Upstream product

• 89976-27-2 methyl ester of 4-iodo-3-nitrobenzoic acid 
• 92050-16-3 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine 
• 619-44-3 methyl 4-iodobenzoate 
• 619-58-9 4-iodobenzoic acid 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 

Downstream Products

• 259219-21-1 4-[methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-amino]-3-nitro-benzoic acid methyl ester 
• 259219-24-4 3-amino-4-[methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-amino]-benzoic acid methyl ester 
• 259219-27-7 3-(4-Methoxycarbonyl-benzoylamino)-4-[methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-amino]-benzoic acid methyl ester 
• 259219-30-2 12-(4-methoxycarbonyl-phenyl)-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diaza-benzo[4,5]cyclohepta[1,2-b]naphthalene-2-carboxylic acid methyl ester 
• 1227244-11-2 3-amino-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 
• 1227244-15-6 C₂₄H₃₀N₂O₃ 

Relevant articles and documents

RXR partial agonist CBt-PMN exerts therapeutic effects on type 2 diabetes without the side effects of RXR full agonists

Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.